According to a report by Carl Zimmer in The New York Times, Tabula Bioscience says it performed much of the research behind a novel treatment that its former partner, Radical Numerics, announced. The claim raises a question about credit for the work.

The Times reported that Radical Numerics had drawn attention with its announcement about the treatment. The summary describes the announcement only as having drawn attention, without detail about the treatment. The report's headline describes a biotech firm claiming some credit for virus research, and the Times identifies Tabula as a former partner of Radical Numerics.

According to the Times, the two companies are no longer partners, but the summary does not say why the partnership ended or when. It also does not say how the two companies divided the work or what share of the research each performed.

The Times summary does not say whether Radical Numerics has responded to Tabula's claim, and it does not describe what the treatment does or how it was tested. No account from Radical Numerics is included in the summary, and no second outlet's reporting was available for comparison.

The Times report was published on November 6, 2026, under the byline of Carl Zimmer, and its web address places it in the newspaper's science section.

This account rests on a single source, the Times summary, and is limited to what that summary states. Details in the full report may go beyond it.

Sources: The New York Times: Biotech Firm Claims Some Credit for Groundbreaking Virus Research.